CD9

Across TCGA pan-cancer cohorts, CD9 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CD9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD9 RNA is repressed in tumor relative to normal tissue. In most cancer types CD9 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

KIRC, LUAD, and BRCA are the cancer types where CD9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.869	<.001	10	view →
LUAD	All	III,IV	−0.937	<.001	7	view →
BRCA	All	III,IV	+1.126	<.001	6	view →
KIRP	All	All	−0.902	<.001	5	view →
LUSC	All	All	+0.721	<.001	4	view →
COAD	Female	All	+0.399	.005	4	view →
BLCA	Female	All	+0.671	.024	3	view →
LIHC	All	All	+0.477	.010	3	view →
PRAD	All	All	−0.355	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CD9–KIRC

Open the KIRC breakdown →